Aarti Industries is a global speciality chemicals manufacturer that turns basic industrial feedstocks-benzene, toluene, nitric acid and chlorine-into over 100 products used in everything from agrochemicals and pharmaceuticals to electric-vehicle polymers and energy additives. Founded in 1984 by first-generation technocrats with a single Nitro Chloro Benzene unit in Gujarat, the company has grown into a top-1-to-4 global producer for three-quarters of its portfolio, serving more than 1,100 customers across 60 countries. The recurring approach that explains the whole business is a relentless drive to lock in long-term customer contracts, then backward-integrate into the underlying chemistry so it controls the cost and reliability of every step-a model it calls combining “process chemistry competence with scale-up engineering competence”.
Business segments
Three engines at different stages-a benzene-based speciality-chemicals powerhouse that generates the bulk of revenue, a pharmaceuticals platform that was demerged into a separate listed entity, and a pair of joint ventures in amines and plastic recycling that are still under construction-each built on the chemistry and customer relationships of the one before.
1. Speciality chemicals: the benzene-based engine that powers the group
A fully integrated manufacturer that takes basic benzene and toluene through multiple chemical steps to produce over 100 speciality intermediates, with more than 85% of revenue coming from customers it has served for over a decade.
- Three value chains, one feedstock backbone - the business runs on fully integrated Benzene, Toluene and Sulphuric Acid chains, producing families such as Nitro Chloro Benzene (NCB), Di-Chloro Benzene (DCB), Phenylenediamines (PDA) and Nitrotoluene (NT), with advanced chemistries like fluorination and photochemistry now commercialised. More than 70% of the portfolio is speciality chemicals tailored for specific applications rather than generic commodities.
- Global top-three positions create a pricing floor - the company ranks #1 globally in DCB, is among the top three in NCB, top two in Hydrogenation and top three in Chlorination and Nitration, and is the only manufacturer in India of the entire PDA value chain and of nitro fluoro aromatics using the Halex process. That concentration means customers have few alternative suppliers who can match the scale and integration.
- Long-term contracts lock in volumes before a plant is built - multi-year supply agreements are the norm, including a $150 million contract with a global agrochemical innovator running to 2030 that requires no new capex, a 9-year agrochemical intermediate contract projecting over ₹3,000 crore, and a 4-year deal worth over ₹6,000 crore with a multinational conglomerate. A 20-year supply contract worth $1,540 million involves proprietary technology shared by the partner, who chose AIL over Indian and Chinese competitors despite AIL having no prior experience with the product.
- Cost pass-through keeps margins stable when raw materials swing - the business operates a pass-through pricing structure that pushes inflationary costs for materials, energy and logistics to customers, so the absolute margin per kilogram stays steady even as input prices move. A 20-year nitric-acid supply contract with Deepak Fertilisers, with take-or-pay obligations, secures over 80% of that critical raw-material need at formula-driven international prices.
- Sixteen plants, five co-generation units and two R&D centres - manufacturing is spread across Gujarat and Maharashtra with 11 Zero Liquid Discharge plants, proximity to ports, and 250-plus scientists developing 45-plus new products in-house in a single year. The footprint includes a greenfield site at Jhagadia Zone IV where a multi-purpose plant and Chloro Toluene project are under commissioning, and a recently expanded ethylation unit at Dahej that can switch between different ethylation and propylation products.
2. Pharmaceuticals: the demerged sibling, now a standalone listed entity
The pharmaceuticals business was separated into Aarti Pharmalabs Ltd in FY22 so each entity could pursue its own capital and regulatory path-AIL today is a pure-play speciality-chemicals company.
- Demerger created focus - effective July 2021 and listed in October 2022, the split gave AIL shareholders one share in Aarti Pharmalabs for every four AIL shares held, while the parent retained an identical promoter and public shareholding pattern. The pharma undertaking included a small backward-integrated speciality-chemicals facility that had been feeding the pharma business and represented less than 3% of speciality-chemicals revenue.
- No longer part of AIL’s operations - post-demerger, AIL does not consolidate or manage the pharmaceuticals segment; it appears in the segment mix only as a legacy reporting line from the period before separation.
Joint ventures and circularity initiatives
Two early-stage platforms extend the speciality-chemicals engine into adjacent chemistries and sustainable materials, using shared investment and partner expertise to limit upfront risk.
- Plastic-recycling JV aims for 500 tonnes a day by 2030 - Aarti Circularity, a wholly owned subsidiary, took a 49% stake in Re Aarti Private Limited in February 2025 to build Plastic Materials Recycling Facilities, with the first site in Hyderabad and commissioning expected during CY26. The company is already engaging with potential buyers of the pyrolysis oil output.
Group structure and partners
AIL is the listed parent, supported by trading subsidiaries in Dubai and the US, a web of renewable-power SPVs, and a 20-year nitric-acid pact that removes a key raw-material risk.
- Trading arms extend global reach - Aarti Chemical Trading FZCO was incorporated in Dubai in September 2023, and its wholly owned step-down subsidiary Aarti Chem Trading USA Inc. was set up in Delaware in October 2024, both to trade and deal in speciality chemicals.
- Nitric acid secured for two decades - the binding contract with Deepak Fertilisers, effective April 2023, covers over 80% of AIL’s nitric-acid requirement with formula-driven international pricing and mutual take-or-pay obligations, eliminating any need to backward-integrate into that input.
- Promoter voting agreement consolidates control - in December 2024, three promoter groups holding a combined 25.66% of AIL entered a shareholders’ voting agreement that requires the CVG group representative to be part of any majority decision, alongside customary rights of first refusal and tag-along provisions.